Next Biomedical Co.,Ltd. (KOSDAQ:389650)
South Korea flag South Korea · Delayed Price · Currency is KRW
33,250
+950 (2.94%)
At close: Aug 24, 2026

Next Biomedical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
232.56-311.082,860-7,522-5,732-16,645
Depreciation & Amortization
533.61518.51492.36467.32463.41433.53
Loss (Gain) From Sale of Assets
--9.81-4.24--5.29-69.58
Asset Writedown & Restructuring Costs
----38.720.8
Loss (Gain) From Sale of Investments
-1,07077.07-113.58-133.56102.4865.86
Stock-Based Compensation
1,2111,1882,1071,486310.27324.19
Other Operating Activities
1,443350.13-6,0052,492-924.4110,046
Change in Accounts Receivable
-1,716-430.04-876.88-617.38-199.44-14.62
Change in Inventory
-529.9-426.83-366.66-228.8-626.88660.13
Change in Accounts Payable
-111.6434.32-44.7813.1440.91-5.08
Change in Other Net Operating Assets
850.79260.33752.12-117.41-1,676-192.62
Operating Cash Flow
842.431,250-1,201-4,160-8,208-5,396
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-1,023-3,152-439.39-64.54-195.07-704.65
Sale of Property, Plant & Equipment
25.5721.314.27-19.47380
Sale (Purchase) of Intangibles
------69.59
Investment in Securities
11,1465,242-25,6264,171-10,785-714.73
Other Investing Activities
-301.42-427.32-299.430.0116.1613.72
Investing Cash Flow
9,8471,684-26,3614,106-10,945-1,095

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-----2,400
Long-Term Debt Issued
-1,080369931500-
Total Debt Issued
-1,0803699315002,400
Short-Term Debt Repaid
--3,440----1,230
Long-Term Debt Repaid
--971.14-939.53-441.66-451.4-439.48
Total Debt Repaid
-4,687-4,411-939.53-441.66-451.4-1,669
Net Debt Issued (Repaid)
-4,687-3,331-570.53489.3448.6730.52
Issuance of Common Stock
3,6132,23628,920484.2946.56-
Other Financing Activities
---0-0-0-0
Financing Cash Flow
-1,074-1,09528,349973.6395.1721,728

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
305.71-0.35260.79-31.7455.2639.87
Net Cash Flow
9,9221,8391,048888.07-19,00215,276

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-180.14-1,902-1,640-4,225-8,403-6,101
Free Cash Flow Growth
------
Free Cash Flow Margin
-1.01%-11.54%-17.18%-86.53%-300.65%-269.08%
Free Cash Flow Per Share
-22.05-233.95-227.68-672.87-1353.18-1260.87
Levered Free Cash Flow
-4,507-4,293-3,155-3,756-6,103-31,008
Unlevered Free Cash Flow
-4,338-4,063-2,830-3,397-5,877-30,125

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
274.04486.43524.36572.14354.01241.79
Cash Income Tax Paid
59.94--63.92-1.7615.73
Change in Working Capital
-1,507-562.22-536.21-950.45-2,462447.81